GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Net Income (Continuing Operations)

Acrux (ASX:ACR) Net Income (Continuing Operations) : A$-0.71 Mil (TTM As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Acrux Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Acrux's Net Income (Continuing Operations) for the six months ended in Dec. 2023 was A$-3.24 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.71 Mil.


Acrux Net Income (Continuing Operations) Historical Data

The historical data trend for Acrux's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Net Income (Continuing Operations) Chart

Acrux Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.33 -9.47 -12.63 -9.83 -0.76

Acrux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.47 -4.36 -3.29 2.53 -3.24

Acrux Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.71 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux  (ASX:ACR) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


Acrux Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Acrux's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux (ASX:ACR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Net Income (Continuing Operations)
Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.